title: [Our experience with 1 mg BCG vaccine instillation in T1 stage cancer of the bladder].
abstract: We studied 67 patients with bladder cancer in stage T1, with terminated BCG treatment and in pursuit. No stage Ta neither carcinoma in situ was included. The protocol was: beginning of treatment upon retiring vesical catheter, instilation of 1 mg of liofilized BCG vaccine (16 x 10(6) bacilles) in 40-50 ml of intravesical saline solution. A weekly instilation during the first month. An instilation each 15 days during the second and third month and one monthly until complete 12 months of treatment. Also was carried out an study of T lymphocites and cytokines.
  
  
  RESULTS
  The average followup of the 67 patients treated was 51.3 months. 17 patients relapses (25.4%). A 33% were grade 3 and 27% grade 2. Like complications there was a case of inguinal TBC adenititis, 2 TBC prostatitis, 2 TBC cistitis and 5 cases of slight disuric syndrome. The study of subpopulations of lymphocites in peripheral blood demonstrated a significant increase of CD3 and CD4/CD8 ratio. The interleukin 2 measurement in serum also increased significantly after the BCG instilations.
  
  
  CONCLUSIONS
  Our protocol gets similar results to the higher doses, but with minimal complications diminishing the relapses of the tumors in stage T1. A monthly maintenance dose would help to maintain immunity.
authors.affiliation: Unidad de Urología, Facultad de Medicina, Universidad de La Frontera de Temuco-Chile.
authors.forename: P
authors.initials: P
authors.lastname: Rivera
authors.forename: M
authors.initials: M
authors.lastname: Orio
authors.forename: J
authors.initials: J
authors.lastname: Hinostroza
authors.forename: P
authors.initials: P
authors.lastname: Venegas
authors.forename: P
authors.initials: P
authors.lastname: Pastor
authors.forename: M
authors.initials: M
authors.lastname: Gorena
authors.forename: M
authors.initials: M
authors.lastname: Lagos
authors.forename: R
authors.initials: R
authors.lastname: Pinochet
mesh_terms: D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
chemical_list: D001500:BCG Vaccine